Pops Diabetes wins FDA clearance for blood glucose monitoring system

Pops Diabetes Care said this week that the FDA cleared its Pops! one blood glucose monitoring system.

The Minneapolis-based company’s device can be attached directly to the back of a mobile phone and interacts with the user through a coaching app. The Pops! one system also allows users to review their blood glucose trends and share the data with family members and healthcare professionals.

Pops Diabetes Care said it expects to launch the commercialization process in early 2019.

“We are thrilled to have successfully worked with the FDA to clear this novel solution for people with diabetes. POPS! is delivering a simple experience to help people take action to achieve their goals,” CEO Lonny Stormo said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW